{
  "cohort": "ER+/HER2- MBC, 2L, Medicare, by Regimen (2024–2025)",
  "insight_type": "Medicare Regimen Variation",
  "summary": "Abemaciclib is underutilized at 24% in Medicare patients, 14% below peer average. Closing this gap could yield $52,000/year.",
  "chart": {
    "type": "bar",
    "unit": "regimen",
    "data": [
      { "name": "Palbociclib", "value": 44, "gap": 6, "highlight": false },
      { "name": "Abemaciclib", "value": 24, "gap": -14, "highlight": true },
      { "name": "Ribociclib", "value": 46, "gap": 8, "highlight": false }
    ],
    "benchmark": 38,
    "nccn_target": 38
  },
  "financial_impact": {
    "annual_opportunity": "$52,000/year",
    "math": "$52,000/year = 14 Medicare patients × $3,700 margin per patient"
  },
  "clinical_impact": {
    "description": "Improving abemaciclib utilization in Medicare patients increases GI symptom-free survival.",
    "quantitative": "+6.5 months PFS"
  },
  "peer_comparison": {
    "description": "Medicare peer average across regimens is 38%.",
    "peer_benchmark": 38
  },
  "weighted_score": 76,
  "action_steps": [
    "Review Medicare formulary for abemaciclib",
    "Educate providers on managing abemaciclib side effects in Medicare patients",
    "Implement patient assistance programs for abemaciclib"
  ],
  "suggestions": [
    "Negotiate with payers for improved abemaciclib coverage"
  ],
  "drilldowns": [
    {
      "label": "By Age Group",
      "cohort": "ER+/HER2- MBC, 2L, Medicare, Abemaciclib, by Age",
      "jsonFile": "breast-cancer-cdk46-medicare-abemaciclib-by-age.json",
      "drilldownLevel": 3
    }
  ]
} 